Lingzhi Hong
The University of Texas MD Anderson Cancer Center(US)The University of Texas MD Anderson Cancer Center(US)Guangdong Medical College(CN)Scripps MD Anderson Cancer Center(US)Affiliated Hospital of Guangdong Medical College Hospital(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Cancer Genomics and Diagnostics, Lung Cancer Diagnosis and Treatment
Most-Cited Works
- → Structure-based classification predicts drug response in EGFR-mutant NSCLC(2021)427 cited
- → Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status(2021)351 cited
- → Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer(2021)274 cited
- → Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC(2020)186 cited
- → Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer(2021)118 cited
- → Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study